Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17621542 | 0.94 | KDM4C (0.55) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621535 | 0.93 | KDM4C (0.49) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621543 | 0.92 | KDM4C (0.49) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621537 | 0.91 | KDM4C (0.47) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621538 | 0.91 | KDM4C (0.46) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621775 | 0.91 | KDM4C (0.46) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621782 | 0.90 | KDM4C (0.46) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL19272940 | 0.90 | KDM4C (0.46) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621536 | 0.90 | KDM4C (0.55) | KDM4CKDM2BPHF8KDM2AKDM5A | |
| SCHEMBL17621776 | 0.89 | KDM4C (0.45) | KDM4CKDM2BPHF8KDM2AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-9676770-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240529-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885KDM2B 15/4885PHF8 35/4885 |
| US-20160108033-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885KDM2B 15/4885PHF8 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.